Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Down 22.4% in December

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totaling 77,875 shares, a drop of 22.4% from the December 15th total of 100,401 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average trading volume of 90,581 shares, the days-to-cover ratio is presently 0.9 days. Based on an average trading volume of 90,581 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.6% of the company’s stock are short sold.

Institutional Trading of Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. Citadel Advisors LLC bought a new stake in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,486 shares of the company’s stock, valued at approximately $41,000. Citadel Advisors LLC owned about 0.07% of Genenta Science as of its most recent filing with the Securities and Exchange Commission. 15.13% of the stock is currently owned by hedge funds and other institutional investors.

Genenta Science Stock Performance

Genenta Science stock traded down $0.08 during mid-day trading on Friday, hitting $1.30. The company had a trading volume of 80,660 shares, compared to its average volume of 72,095. Genenta Science has a 1 year low of $1.28 and a 1 year high of $10.00. The business has a fifty day moving average of $1.67 and a 200 day moving average of $2.81.

Genenta Science (NASDAQ:GNTA) last issued its earnings results on Friday, October 10th. The company reported ($0.10) earnings per share (EPS) for the quarter. Research analysts forecast that Genenta Science will post -0.93 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genenta Science in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Genenta Science presently has a consensus rating of “Sell”.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.